Analgesia Clinical Trial Experience
Experience in just about every type of pain and major class of analgesics, including every NSAID analgesic on the market today. Leverage our experience as you tackle the most innovative areas of analgesia research.
We’re known for analgesia
Laying the foundation for modern pain research
Much of the foundation for modern analgesia research was built here, and we have conducted more studies than any other CRO.
We have performed more than 870 trials across every type of pain, and many of the pain models that are today’s industry standards were invented here. With industry-leading access to patients, sites, and motivated investigators, we get trials running quickly.
Why choose Premier?
- Unequaled expertise in chronic and acute pain, spanning from disk disease to dental pain
- Extensive experience in fibromyalgia with 13 studies conducted over the past five years
- Postoperative bunionectomy model reduces patient recruitment time by up to 40 percent without sacrificing assay sensitivity
Mitigating the placebo response
The etiology of the placebo effect is multifactorial and includes an expectation of benefit, response bias, and psychological or cultural factors. We explore how trial designs and training programs may be used to help reduce the placebo effect in analgesia clinical trials.
Neuropathic pain trial sites
Of all the truisms that apply to clinical drug research, probably none is more universally accepted than this one: “There’s no substitute for experience.” But if you’re working in an indication that is not widely studied, selecting sites on the basis of experience can be difficult.
Premier Thought Leadership
Scott Millard has spent his 25-plus year career focused in analgesia study delivery overseeing the strategy through to execution for analgesia programs. Mr. Millard’s leadership of the analgesia business and study execution expertise is the perfect pairing to provide sponsors with clean data that can be used confidently to support the marketing applications for their drugs in development.